Home » Stocks » JUPW

Jupiter Wellness, Inc. (JUPW)

Stock Price: $4.18 USD 0.09 (2.20%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 49.78M
Revenue (ttm) 1.07M
Net Income (ttm) -6.29M
Shares Out 11.26M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.18
Previous Close $4.09
Change ($) 0.09
Change (%) 2.20%
Day's Open 4.29
Day's Range 4.04 - 4.33
Day's Volume 94,227
52-Week Range 3.60 - 8.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Four Indications in Clinical Development JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellnes...

1 week ago - Accesswire

Accretive acquisition would add a profitable company with approximately $28 million of revenue in 2020 (unaudited) JUPITER, FL / ACCESSWIRE / April 20, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a lea...

2 weeks ago - Accesswire

JUPITER, FL / ACCESSWIRE / April 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has appoin...

3 weeks ago - Accesswire

JUPITER, FL / ACCESSWIRE / March 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a CBD-based pharmaceuticals company with 4 significant treatments in skin health for eczema, skin cancer, burns and herp...

1 month ago - Accesswire

Ecommerce site is expanded and optimized for Company's growing portfolio of CBD wellness products JUPITER, FL / ACCESSWIRE / March 2, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a CBD-based pharmaceuti...

2 months ago - Accesswire

Data Expected Q1 2021 From Study of 66 Patients JUPITER, FL / ACCESSWIRE / December 22, 2020 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics a...

4 months ago - Accesswire

About JUPW

Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for use in the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CaniSun, a CBD-infused su... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Oct 30, 2020
Stock Exchange
NASDAQ
Ticker Symbol
JUPW
Full Company Profile

Financial Performance

In 2020, JUPW's revenue was $1.07 million, an increase of 16,409.14% compared to the previous year's $6,455. Losses were -$6.29 million, 579.6% more than in 2019.

Financial Statements